BioLamina

Dr. Ed Keebler

🇫🇷 France

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Bertha Cremin

🇮🇹 Italy

9.1

Reviewed: September 5, 2024

• - Pharmacovigilance Services
• - Ongoing
• - Pharmaceutical Company

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Daniel Roob

🇺🇸 United States

9.5

Reviewed: April 10, 2023

• - Gene Therapy Development
• - 12 weeks January - March 2023
• - Research Institution

The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.

Bernard Schumm

🇮🇳 India

9

Reviewed: June 9, 2024

• - Process Development
• - 12 weeks March - May 2024
• - Biotech Company

The process development services enhanced our manufacturing efficiency significantly. The team's expertise in process optimization was evident, and they provided valuable insights that improved our production workflow.

Winifred Jacobi

🇺🇸 United States

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Ora Klocko

🇬🇧 United Kingdom

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.